Main Article Content
Background: Chronic spontaneous urticaria (CSU) affects a large percentage of children and can have a serious negative impact on their quality of life. Autologous serum therapy (AST) has become a promising treatment for CSU, although more research is needed to determine how safe and beneficial it is for paediatric patients.
The purpose of this prospective study was to assess the efficacy and security of AST in CSU-affected children.
Methods: The study included 100 kids who had been diagnosed with CSU in total. The Urticaria Activity Score (UAS), the primary outcome measure, and the Quality of Life (QoL) score, the secondary end measure, were evaluated at baseline and following the administration of AST for a total of 12 weeks. Adverse AST-related occurrences were also kept an eye on.
Results: The UAS scores significantly decreased after AST (p< 0.001), indicating better illness management. The QoL scores also showed a substantial improvement (p<0.001), which was indicative of greater wellbeing. The few adverse effects that did occur were mostly local erythema and moderate discomfort at the injection site.
Conclusion: The results of this study show that AST is both beneficial and safe in lowering disease activity and enhancing quality of life in children with CSU. The prospective treatment alternative provided by AST has a good safety profile, making it an important factor to take into account while managing CSU in paediatric patients.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy. 2018;73(7):1393-1414.
Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317-330.
Ozkan M, Oflaz SB, Kocaman N, Ozseker F, Gelincik A, Büyüköztürk S, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2007 Jul;99(1):29-33. doi: 10.1016/S1081-1206(10)60617-5. PMID: 17650826..
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul;69(7):868-87. doi: 10.1111/all.12313. Epub 2014 Apr 30. PMID: 24785199.
Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW. A serological mediator in chronic idiopathic urticaria—a clinical, immunological and histological evaluation. Br J Dermatol. 1986;114(5):583-590.
Chang HC, Sung CW, Lin MH. Efficacy of autologous whole blood or serum therapy for chronic spontaneous urticaria: a systematic review and meta-analysis. J Dermatolog Treat. 2019 Dec;30(8):818-825. doi: 10.1080/09546634.2019.1572863. Epub 2019 Jun 24. Erratum in: J Dermatolog Treat. 2019 Dec;30(8):I. PMID: 30661442.
Patil S, Sharma N, Godse K. Autologous serum therapy in chronic urticaria. Indian J Dermatol. 2013;58(3):225-226. doi:10.4103/0019-5154.110833
Agarwal A, Jena AK, Dash M, Panda M. Efficacy and Safety of Autologous Serum Therapy in Chronic Spontaneous Urticaria in the Pediatric Population: A Prospective Pilot Study. Indian Dermatol Online J. 2023;14(2):195-199. Published 2023 Mar 3. doi:10.4103/idoj.idoj_376_22.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197-201
Anderson K, Putterman E, Rogers RS, Patel D, Treat JR, Castelo-Soccio L. Treatment of severe pediatric atopic dermatitis with methotrexate: A retrospective review. Pediatr Dermatol. 2019 May;36(3):298-302. doi: 10.1111/pde.13781. Epub 2019 Feb 27. PMID: 30811669..
Greaves MW. Chronic urticaria in childhood. Allergy. 2000;55(4):309-320.
Staubach P, Onnen K, Vonend A, Metz M, Siebenhaar F, Tschentscher I, et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: A placebo-controlled trial. Dermatology. 2006;212(2):150-159.
Kocatürk E, Kavala M, Kural E. Autologous serum skin test versus autologous plasma skin test in patients with chronic urticaria: A systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(1):194-200.
Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol. 2006 May;117(5):1113-7. doi: 10.1016/j.jaci.2005.12.1343. Epub 2006 Feb 14. PMID: 16675340.